Indaptus Therapeutics, Inc. INDP
We take great care to ensure that the data presented and summarized in this overview for Indaptus Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INDP
View all-
Vanguard Group Inc Valley Forge, PA256KShares$297,2670.0% of portfolio
-
Investment House LLC Las Vegas, NV100KShares$115,9720.01% of portfolio
-
Geode Capital Management, LLC Boston, MA73.1KShares$84,8290.0% of portfolio
-
Strategy Asset Managers LLC45.3KShares$52,5890.01% of portfolio
-
Pine Valley Investments LTD Liability CO Marlton, NJ44.1KShares$51,1380.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny27.1KShares$31,4350.0% of portfolio
-
Vivaldi Capital Management LP Chicago, IL24KShares$27,8390.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il15.4KShares$17,8520.0% of portfolio
-
State Street Corp Boston, MA13.1KShares$15,1640.0% of portfolio
-
Tower Research Capital LLC (Trc) New York, NY4.81KShares$5,5810.0% of portfolio
Latest Institutional Activity in INDP
Top Purchases
Top Sells
About INDP
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Insider Transactions at INDP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 08
2024
|
Jeffrey A Meckler CEO and Director |
BUY
Grant, award, or other acquisition
|
Direct |
84,932
+34.63%
|
$84,932
$1.82 P/Share
|
|
Aug 14
2023
|
Glen R. Anderson > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
23,934
+1.97%
|
$47,868
$2.34 P/Share
|
|
Aug 11
2023
|
Glen R. Anderson > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
35,064
+2.92%
|
$70,128
$2.12 P/Share
|
|
Aug 10
2023
|
Glen R. Anderson > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
44,354
+3.77%
|
$44,354
$1.94 P/Share
|
|
Dec 01
2022
|
Boyan Vesselinov Litchev Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
500
+30.3%
|
$500
$1.87 P/Share
|
|
Nov 22
2022
|
Boyan Vesselinov Litchev Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
500
+43.48%
|
$500
$1.83 P/Share
|
|
Nov 21
2022
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
9,600
+11.3%
|
$9,600
$1.9 P/Share
|
|
Nov 18
2022
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
400
+0.6%
|
$400
$1.76 P/Share
|
|
Sep 08
2022
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
10,308
+13.62%
|
$20,616
$2.8 P/Share
|
|
Sep 07
2022
|
Walt Addison Linscott Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
150
+50.0%
|
$300
$2.62 P/Share
|
|
Sep 07
2022
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
8,632
+13.55%
|
$17,264
$2.57 P/Share
|
|
Sep 06
2022
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
1,060
+2.23%
|
$2,120
$2.44 P/Share
|
|
Jun 06
2022
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
19,727
+30.3%
|
$39,454
$2.63 P/Share
|
|
Mar 02
2022
|
Boyan Vesselinov Litchev Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
50
+25.0%
|
$200
$4.09 P/Share
|
|
Feb 01
2022
|
Michael James Newman CSO and Director |
SELL
Open market or private sale
|
Indirect |
14,130
-1.02%
|
$70,650
$5.0 P/Share
|
|
Jan 31
2022
|
Boyan Vesselinov Litchev Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
100
+50.0%
|
$400
$4.65 P/Share
|
|
Jan 31
2022
|
Michael James Newman CSO and Director |
SELL
Open market or private sale
|
Indirect |
5,870
-0.42%
|
$29,350
$5.0 P/Share
|
|
Nov 18
2021
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
11,187
+30.37%
|
$55,935
$5.82 P/Share
|
|
Sep 14
2021
|
Jeffrey A Meckler CEO and Director |
BUY
Open market or private purchase
|
Direct |
12,000
+45.35%
|
$84,000
$7.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 84.9K shares |
|---|